Enterprise Value
1.126B
Cash
339.5M
Avg Qtr Burn
-23.84M
Short % of Float
8.10%
Insider Ownership
1.72%
Institutional Own.
98.42%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer | Phase 2/3 Initiation | |
Darovasertib Details Solid tumor/s, Cancer, Uveal melanoma | Phase 2 Interim update | |
IDE397 (MAT2A) Details Solid tumor/s, Cancer | Phase 1/2 Interim update | |
IDE161 Details Solid tumor/s, Cancer, ER+/HER2- breast cancer | Phase 1 Data readout |